Novo Nordisk A/ S stock (DK0062498333): weight-loss momentum and fresh Q1 2026 numbers in focus

Novo Nordisk A/S has delivered new Q1 2026 results while demand for its obesity and diabetes drugs remains strong, keeping the stock in focus for global and US investors alike.

Novo Nordisk A/S remains at the center of investor attention after publishing its results for the first quarter of 2026 and updating on the continuing demand for its GLP-1 diabetes and obesity treatments, according to a company release dated 05/02/2026 on the investor relations website Novo Nordisk IR as of 05/02/2026. The group reported double-digit sales growth driven primarily by obesity care and the continued rollout of its weight-loss drug Wegovy in additional markets, as well as strong performance from its diabetes therapy Ozempic, according to the same Q1 2026 statement and presentation on 05/02/2026 Novo Nordisk IR as of 05/02/2026.

As of: 22.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novo-Nordisk
• Sector/industry: Pharmaceuticals, diabetes and obesity care
• Headquarters/country: Denmark
• Core markets: Global diabetes and obesity treatment markets with strong presence in Europe and North America
• Key revenue drivers: GLP-1 diabetes therapies and obesity drugs including Ozempic and Wegovy
• Home exchange/listing venue: Nasdaq Copenhagen; American Depositary Receipts listed on the New York Stock Exchange (ticker: NVO)
• Trading currency: Danish krone in Copenhagen; US dollar for ADRs in New York

Novo Nordisk A/S: core business model

Novo Nordisk A/S is a global healthcare group focused on treating chronic diseases, with a historical core in insulin and diabetes care and a rapidly growing franchise in obesity and other cardiometabolic conditions, as described in its corporate profile updated 03/2026 on the company website Novo Nordisk corporate profile as of 03/2026. The business model is built on research and development of innovative therapies, large-scale biological manufacturing and a global commercial network that reaches patients in more than 170 countries, according to the same profile published 03/2026 Novo Nordisk corporate profile as of 03/2026.

Historically, Novo Nordisk generated a substantial part of its sales from insulin products and other diabetes treatments; over the last few years, it has shifted toward GLP-1–based therapies, which have become the main engine of growth, according to the 2025 annual report released 02/05/2026 Novo Nordisk annual report 2025 as of 02/05/2026. The company invests heavily in clinical trials to expand indications for its leading molecules, and it leverages premium pricing and large volumes to support profitability, based on the same annual report from 02/05/2026 Novo Nordisk annual report 2025 as of 02/05/2026.

In addition to diabetes and obesity care, Novo Nordisk has smaller but strategically important units in rare blood disorders and rare endocrine diseases, which diversify the portfolio and help balance exposure to reimbursement and pricing pressure in mainstream therapies, according to its 2025 Form 20-F filed with the US Securities and Exchange Commission on 02/06/2026 SEC Form 20-F as of 02/06/2026. The company’s integrated model spans discovery through to commercialization, enabling it to capture value across the entire drug life cycle, as outlined in the same 20-F filed 02/06/2026 SEC Form 20-F as of 02/06/2026.

Main revenue and product drivers for Novo Nordisk A/S

The dominant revenue drivers for Novo Nordisk are its GLP-1–based therapies for type 2 diabetes and obesity, particularly Ozempic and Wegovy, which continued to post strong demand in the first quarter of 2026, according to the Q1 2026 results announcement on 05/02/2026 Novo Nordisk Q1 2026 report as of 05/02/2026. In that period, obesity care reported high double-digit sales growth versus the prior-year quarter, with Wegovy continuing to lead the expansion in the segment, based on the same Q1 2026 report dated 05/02/2026 Novo Nordisk Q1 2026 report as of 05/02/2026.

For diabetes care, the company highlighted continued strong uptake of Ozempic across major markets, including the United States, where GLP-1s have become an important treatment option for adults with type 2 diabetes, according to management comments in the Q1 2026 earnings presentation on 05/02/2026 Novo Nordisk Q1 2026 presentation as of 05/02/2026. While legacy insulin products remain relevant, the revenue mix has shifted markedly toward newer therapies, particularly in North America and Europe, as noted in the 2025 annual report released 02/05/2026 Novo Nordisk annual report 2025 as of 02/05/2026.

Another important revenue component comes from the company’s rare disease portfolio, which includes treatments for hemophilia and growth disorders. Although these products account for a smaller share of total sales compared with obesity and diabetes offerings, they tend to be high-value therapies with specialized patient populations, according to the rare disease segment overview included in the 2025 annual report published 02/05/2026 Novo Nordisk annual report 2025 as of 02/05/2026. The combination of large-scale blockbuster drugs and niche specialty products contributes to the company’s overall revenue resilience, as management emphasized during the Q1 2026 conference call on 05/02/2026 Novo Nordisk Q1 2026 call as of 05/02/2026.

Conclusion

Novo Nordisk A/S has reinforced its position as a leading player in diabetes and obesity care with its Q1 2026 results, which showed ongoing momentum for GLP-1 therapies and strong demand in major markets, including the United States, according to the company’s 05/02/2026 report and presentation Novo Nordisk Q1 2026 report as of 05/02/2026. At the same time, investors are watching capacity expansion, regulatory developments and competition in the obesity space, which could influence future growth and margins, as outlined in the risk factors section of the 2025 Form 20-F filed 02/06/2026 SEC Form 20-F as of 02/06/2026. For US investors following large-cap healthcare and the evolution of weight-loss treatments, Novo Nordisk remains a key company to monitor within the global pharmaceuticals sector.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.